S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 

Enanta Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ENTA)

$9.25
-0.23 (-2.43%)
(As of 12/8/2023 ET)
Compare
Today's Range
$9.15
$9.57
50-Day Range
$8.18
$10.78
52-Week Range
$8.08
$62.06
Volume
154,352 shs
Average Volume
275,290 shs
Market Capitalization
$194.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.88

Enanta Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
244.6% Upside
$31.88 Price Target
Short Interest
Bearish
7.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
-0.80mentions of Enanta Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$118,459 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.44) to ($4.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

210th out of 946 stocks

Biotechnology Industry

11th out of 52 stocks


ENTA stock logo

About Enanta Pharmaceuticals Stock (NASDAQ:ENTA)

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

ENTA Stock Price History

ENTA Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Enanta Pharma Stock (NASDAQ:ENTA) Insider Trades
What 5 Analyst Ratings Have To Say About Enanta Pharma
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Q4 2023 Enanta Pharmaceuticals Inc Earnings Call
Recap: Enanta Pharma Q4 Earnings
Enanta Pharma Q4 2023 Earnings Preview
Enanta Pharmaceuticals earnings preview: what to expect
Enanta Pharmaceuticals Inc ENTA
Analyst Expectations for Enanta Pharma's Future
The Latest Analyst Ratings for Enanta Pharma
See More Headlines
Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/20/2023
Today
12/08/2023
Next Earnings (Estimated)
2/06/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENTA
Employees
145
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.88
High Stock Price Target
$87.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+244.6%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Net Income
$-133,820,000.00
Net Margins
-168.95%
Pretax Margin
-165.39%

Debt

Sales & Book Value

Annual Sales
$79.20 million
Book Value
$10.29 per share

Miscellaneous

Free Float
18,385,000
Market Cap
$194.80 million
Optionable
Optionable
Beta
0.49
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Jay R. Luly Ph.D. (Age 67)
    President, CEO & Director
    Comp: $1.23M
  • Mr. Paul J. Mellett Jr.Mr. Paul J. Mellett Jr. (Age 68)
    Senior VP of Finance & Administration and CFO
    Comp: $650.94k
  • Dr. Yat Sun Or Ph.D. (Age 71)
    Senior VP of Research & Development and Chief Scientific Officer
    Comp: $720.16k
  • Mr. Nathaniel S. Gardiner J.D. (Age 69)
    Senior VP, General Counsel & Secretary
    Comp: $657.95k
  • Dr. Scott T. Rottinghaus M.D. (Age 49)
    Senior VP & Chief Medical Officer
    Comp: $616.73k
  • Ms. Jennifer Viera
    Senior Director of Investor Relations & Corporate Communications
  • Ms. Tara Lynn Kieffer Ph.D. (Age 45)
    Senior Vice President of New Product Strategy & Development
    Comp: $496.85k
  • Mr. Brendan Luu (Age 48)
    Senior Vice President of Business Development
    Comp: $535.8k














ENTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Enanta Pharmaceuticals stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ENTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENTA, but not buy additional shares or sell existing shares.
View ENTA analyst ratings
or view top-rated stocks.

What is Enanta Pharmaceuticals' stock price target for 2024?

8 Wall Street analysts have issued 1-year target prices for Enanta Pharmaceuticals' stock. Their ENTA share price targets range from $14.00 to $87.00. On average, they expect the company's share price to reach $31.88 in the next year. This suggests a possible upside of 244.6% from the stock's current price.
View analysts price targets for ENTA
or view top-rated stocks among Wall Street analysts.

How have ENTA shares performed in 2023?

Enanta Pharmaceuticals' stock was trading at $46.52 at the beginning of 2023. Since then, ENTA stock has decreased by 80.1% and is now trading at $9.25.
View the best growth stocks for 2023 here
.

Are investors shorting Enanta Pharmaceuticals?

Enanta Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,510,000 shares, an increase of 12.7% from the October 31st total of 1,340,000 shares. Based on an average trading volume of 459,800 shares, the days-to-cover ratio is presently 3.3 days. Approximately 7.7% of the company's shares are sold short.
View Enanta Pharmaceuticals' Short Interest
.

When is Enanta Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 6th 2024.
View our ENTA earnings forecast
.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) released its quarterly earnings data on Monday, November, 20th. The biotechnology company reported ($1.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.11) by $0.78. The biotechnology company had revenue of $18.93 million for the quarter, compared to analyst estimates of $17.93 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 52.23% and a negative net margin of 168.95%. During the same quarter in the previous year, the company posted ($1.27) earnings per share.

What ETF holds Enanta Pharmaceuticals' stock ?

ETFMG Treatments Testing and Advancements ETF holds 5,945 shares of ENTA stock, representing 0.75% of its portfolio.

What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO?

5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend.

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (9.97%), Northern Trust Corp (4.56%), Krensavage Asset Management LLC (3.49%), Assenagon Asset Management S.A. (3.00%), Acadian Asset Management LLC (2.61%) and Jacobs Levy Equity Management Inc. (1.64%). Insiders that own company stock include Brendan Luu, Bruce L A Carter, Jay R Luly, Nathalie Adda, Paul J Mellett, Scott T Rottinghaus and Yat Sun Or.
View institutional ownership trends
.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ENTA) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -